Pfizer Inc.PFENYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank7
3Y CAGR-29.6%
5Y CAGR-4.8%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-29.6%/yr
vs +17.6%/yr prior
5Y CAGR
-4.8%/yr
Recent deceleration
Acceleration
-47.2pp
Decelerating
Percentile
P7
Near historical low
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $9.08B | -7.7% |
| 2024 | $9.84B | +105.2% |
| 2023 | $4.79B | -81.6% |
| 2022 | $26.03B | -12.8% |
| 2021 | $29.87B | +157.2% |
| 2020 | $11.61B | +16.2% |
| 2019 | $9.99B | -26.7% |
| 2018 | $13.63B | -4.4% |
| 2017 | $14.25B | +2.5% |
| 2016 | $13.90B | - |